Sunday June 16, 2019

Novel Drug May Shorten Treatment Duration For Tuberculosis

Despite significant progress in combating tuberculosis, it remains the leading infectious cause of death worldwide, he said

0
//

A new experimental antibiotic for tuberculosis (TB) has been shown to be more effective against TB than Isoniazid, a decades old drug which is currently one of the standard treatment for the disease, finds a study on mice.

The new drug, called AN12855, has several advantages over Isoniazid as Isoniazid requires conversion to its active form by a Mycobacterial enzyme, KatG, in order to kill the pathogen, which creates some problems.

In some M. tuberculosis, KatG is nonfunctional. That does not make M. tuberculosis any less pathogenic, but it prevents the drug from working. Consequently, this creates an easy avenue for the development of drug resistance.

In the study, the new drug showed a much lower tendency to develop resistance, and it remains in the tissues where the Mycobacterium tuberculosis bacteria reside for longer, killing them more effectively.

WHO will start working towards ending Tuberculosis
Dr. Simon Angelo (L) examines Iman Steven suffering from tuberculosis, held by her mother (R) at the hospital of Doctors Without Borders (MSF), June 15, 2016, at the Protection of Civilians (PoC) site in Malakal, South Sudan. VOA

The goal of TB drug development programmes is to develop universal treatment regimens that will shorten and simplify TB treatment in patients, which typically takes at least six months, and sometimes more than a year, said lead author Gregory T. Robertson, Assistant Professor at the Colorado State University in Fort Collins in the US.

For the study, the researchers used a new TB mouse model that develops these M. tuberculosis-containing granulomas to compare Isoniazid and AN12855.

Granuloma refers to a mass of granulation tissue, typically produced in response to infection, inflammation, or the presence of a foreign substance.

“We discovered that the drugs differed dramatically with respect to their abilities to kill the pathogen in highly diseased tissues,” said Robertson.

Tuberculosis
New TB drug may shorten treatment duration: Study. IANS

AN12855 proved more effective, “without selecting for appreciable drug resistance”, added Robertson in the study published in the journal Antimicrobial Agents and Chemotherapy.

Despite significant progress in combating tuberculosis, it remains the leading infectious cause of death worldwide, he said.

Also Read- Oscar Nominees Furious Over Exclusion From Telecast

“Multidrug resistance is a further challenge to the mission to control TB globally. Collectively, our group has pioneered the use of new TB mouse efficacy models to help advance innovative new therapies designed to shorten the length of TB treatment.” (IANS)

Next Story

Super Drug to Take on Stubborn Tuberculosis in Uttar Pradesh, India

Another pill with bedaquiline has already been introduced in the state to fight excessively drug resistant (XDR) TB

0
Drug, Tuberculosis, Uttar Pradesh
The new anti-TB drug, with delamanid as active substance, is currently administered to patients. Pixabay

Uttar Pradesh may soon get a new drug to fight the multi-drug resistant (MDR) tuberculosis (TB).

The new anti-TB drug, with delamanid as active substance, is currently administered to patients — primarily children in the age group of six to 17 years — in a few southern states of India and is yet to be introduced in Uttar Pradesh, which reported 4.22 lakh patients in 2018.

According to the State TB officer Santosh Gupta, “Delamanid would be introduced in UP in the third quarter of the year, as per the central guidelines.”

“We are awaiting procurement of the drug from the union government. Four of our officers have been trained for implementation of it, which will be given to children (9-17 years) with MDR-TB,” the doctor added.

Drug, Tuberculosis, Uttar Pradesh
Uttar Pradesh may soon get a new drug to fight the multi-drug resistant (MDR) tuberculosis (TB). Pixabay

Gupta said that another pill with bedaquiline has already been introduced in the state to fight excessively drug resistant (XDR) TB and for which 18 nodal drug resistance centres have been set up.

“An XDR-TB patient is resistant to all anti-TB drugs, including even the stronger combinations of medicines. It is an advanced form of MDR-TB. Bedaquiline, which is WHO recommended, has been made available to patients for free and is found to be effective,” said Gupta and added that patients were being kept under close observation for side effects.

He further laid emphasis on the early detection of TB cases.

Also Read- Chandrayaan-2 will be Launched on July 15, Land on Moon on Sept 6/7

Meanwhile, chairman of the UP state task force for TB control and head of KGMU’s respiratory medicine department, Professor Suryakant said: “Around 28 lakh TB patients are recorded in India. If nutrition is not received in the form of lentils/pulses, fruits and vegetables in diet, a person is more susceptible to the TB bacteria.” (IANS)